Novartis re-launches patient education program

Share this article:
Novartis has embarked "on a mission" to fight hypertension while backing its best-selling product, the blood-pressure-lowering medication Diovan, according to the drugmaker's top financial official.
"We are on a mission in hypertension because we think there is a lot of unmet [patient] need," said Novartis chief operating officer Alex Gorsky speaking at Bear Stearns' annual healthcare conference in New York.
To help achieve its goal of "lowering America's blood pressure," Novartis rebranded and reformatted its Take Action for Healthy BP patient education program as the BP Success Zone. The renamed program, featuring a new compliance component, was launched in July.
BP Success Zone helps patients by providing medication, a free Omron blood pressure monitor with rebate, customized patient education that features lifestyle modification action plans, and a members' Web site with blood pressure tracking tools.
The new compliance component to the program helps promote smoking cessation, a low salt diet, exercise, weight reduction and stress reduction.
Diovan is Novartis' top-selling product, with global sales in the 12 months to June 2005 topping the $1.7 billion dollar mark, according to company figures.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.